Owens & Minor Inc
Change company Symbol lookup
Select an option...
OMI Owens & Minor Inc
PSA-U Public Storage
BAC Bank of America Corp
GM General Motors Co
GLW Corning Inc
GILD Gilead Sciences Inc
GG Goldcorp Inc
GEN Genesis Healthcare Inc
GE General Electric Co
GD General Dynamics Corp

Health Care : Health Care Providers & Services | Small Cap ValueCompany profile

Owens & Minor, Inc. is a healthcare services company that connects the world of medical products to the point of care. The Company provides supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies and devices. The Company operates through three segments, which includes Domestic, International and Proprietary Products. The Company’s domestic segment focuses on United States distribution, logistics and value-added services business. The Company’s International segment focuses on European distribution, logistics and value-added services business. The Company’s proprietary products segment provides product-related solutions, including surgical and procedural kitting and sourcing. The Company provides its services to hospitals, integrated healthcare systems, group purchasing organizations, and the United State federal Government, manufacturers of life-science and medical devices, supplies and pharmaceuticals.

Closing Price
Day's Change
-1.39 (-17.51%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Cirrus Logic target cut at Susquehanna as analyst says negative revision was worse than expected

9:33 am ET December 4, 2018 (MarketWatch)

Susquehanna analyst Christopher Rolland lowered his price target on shares of Cirrus Logic Inc. (CRUS) to $43 from $48 on Tuesday, after the Apple Inc. (AAPL) supplier delivered a negative pre-announcement the prior afternoon. Given that other suppliers have cut their outlooks in recent weeks and that Cirrus shares fell sharply when Lumentum Holdings Inc. (LITE) delivered its warning in November, Rolland had assumed that most of the negative risk was priced into shares but called the new projections from Cirrus "a bit worse than we had expected." He has a positive rating on the stock and hopes that management will "revisit longer-term plans to ramp operating expenditures year over year." Oppenheimer's Rick Schafer also chimed in on the negative preannouncement. "We continue to see disappointing iPhone units and a lack of incremental Cirrus content at Apple (82% of revenues in F2Q) hindering growth," he wrote. Schafer has a perform rating on shares, which are down 3.1% in Tuesday morning trading. Apple shares are off 1.6% following the Cirrus warning and a downgrade to neutral (http://www.marketwatch.com/story/apple-stock-falls-after-hsbc-downgrade-2018-12-04) at HSBC. Cirrus's stock has fallen 29% so far this year, while the S&P 500 has risen 4.1%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 04, 2018 09:33 ET (14:33 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.